Treating With CAR T-Cell Therapy in Second-Line B-Cell Lymphoma

Oncologists Discuss CAR T Logistics and Bridging in Relapsed DLBCL

Explore how REMS removal streamlines CAR T-cell access in second-line DLBCL, plus smart bridging options and who qualifies when relapse strikes fast.

Navigating CAR T Decision-Making in R/R DLBCL

Experts break down second-line CAR T for relapsed DLBCL—who qualifies, what to expect, and why logistics still block access.

Considerations for CAR T Therapy in R/R Large B-Cell Lymphoma

During a live event, Paolo Strati, MD and participants explore when to use CAR T in relapsed LBCL, how bispecific antibodies fit, and practical scan, access, and frontline CD19 strategy shifts.

Navigating CAR T Therapy Pathways in R/R Large B-Cell Lymphoma

During a live event, Paolo Strati, MD and participants explored anti‑CD19 CAR T options for relapsed LBCL—including eligibility and eased REMS rules.

Key Takeaways From Long-Term Follow-Up of Early CAR T in LBCL

During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.

Early Relapse Guides Use of CAR T vs Other Options in LBCL

During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell therapy, autologous stem cell therapy, or other treatment options.

Early Split Between Responders and Others Shown With CAR T in DLBCL

During a live event, Ann F. Mohrbacher, MD, discussed outcomes from the latest follow-up of the ZUMA-7 and TRANSFORM trials.

Early Relapsed DLBCL Requires Disease Control to Make CAR T Successful

During a live event, Ann F. Mohrbacher, MD, reviewed treatment options for a patient with early relapsed diffuse large B-cell lymphoma.

Prompt Management of CRS After CAR T for DLBCL Is Essential

During a live event, Nathan Denlinger, DO, MS, discussed outcomes of the ZUMA-7 trial in diffuse large B-cell lymphoma.

Elimination of REMS Program Could Reduce Barriers to CAR T in DLBCL

During a live event, Nathan Denlinger, DO, MS, discussed bridging therapy and patient barriers to CAR T-cell therapy.